Connect with us

Technology

QL Biopharm Announces Abstract on Novel Ultra Long-acting GLP-1RA to be Presented at EASD Annual Meeting 2024

Published

on

– Abstract on data from a two-part phase 1c, multiple ascending dose study accepted for oral presentation –

– New data highlighting the Company’s lead drug candidate ZT002 for obesity –

BEIJING, Sept. 3, 2024 /PRNewswire/ — Beijing QL Biopharmaceutical Co., Ltd. (“QL Biopharm”), a clinical stage biopharmaceutical company developing innovative biologic drugs for the treatment of metabolic diseases, today announces that an abstract on its lead drug candidate ZT002 will be presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2024, Madrid, Spain on Thursday 12 September 2024.

QL Biopharm’s lead asset, ZT002 is a novel ultra long-acting glucagon-like peptide-1 receptor agonist (“GLP-1 RA”) in development for obesity with monthly subcutaneous administration. The phase 1c, randomized, placebo-controlled, double-blind multiple ascending dose study was conducted in 28 patients with obesity. Patients were randomly assigned to receive either ZT002 or placebo. Results from the study showed that ZT002 had a favorable safety and tolerability profile. Further, ZT002 induced clinically meaningful weight loss with associated cardiometabolic improvements.

Dr. Zhang Xujia, Ph.D., Founder, Chairman and Chief Executive Officer of QL Biopharm said: “The emerging profile of ZT002 holds great promise as a new standard of care for patients living with obesity. The safety and tolerability seen in patients receiving ZT002 is aligned with the GLP-1RA class. ZT002 has the potential to simplify obesity treatment. We look forward to advancing our ongoing studies and further exploring the potential of ZT002 for weight management and type 2 diabetes treatment.”

Details of the EASD Annual Meeting 2024 poster presentation are as follows:

Title: ZT002, a novel ultra long-acting glp-1 receptor agonist in adults with overweight or obesity: a randomized, placebo-controlled, multiple ascending dose phase 1c study

Session: OP 25 Incretin receptor agonists: better and better

Date and Time: Thursday, 12 September 2024, 11:15 – 11:30 CEST

Presenter: Linong Ji, MD, Professor of Medicine at Peking University People’s Hospital

Location: Madrid Hall

Abstract Number: 147

For more information about the EASD Annual Meeting 2024, including details related to accepted abstracts and presentations, please visit its website. The Abstract is available on the EASD online planner here.

NOTES TO EDITORS

About QL Biopharm

QL Biopharm is a clinical-stage biopharmaceutical company focused on developing novel best-in-class peptide therapeutics for metabolic diseases. The Company leverages its proprietary E. coli manufacturing process enabling rapid and cost-effective scaling of manufacturing for high volume markets. The lead drug candidate, ZT002, is an ultra long-acting subcutaneously administered GLP-1 receptor agonist, currently in a Phase 2 study for obesity and in Phase 1 for type 2 diabetes. In Phase 1 studies, ZT002 demonstrated compelling weight loss and tolerability consistent with the GLP-1 RA class. The Company is also advancing a broader portfolio of novel preclinical assets for the treatment of metabolic diseases, in addition to its biosimilar semaglutide program, currently in Phase 3. QL Biopharm is led by a team of pharma industry veterans with expertise in E. coli–based peptide manufacturing and the development of drugs for metabolic diseases. The Company is backed by leading professional life science investors.

For additional information, please visit https://qlbiopharm.com/

About EASD

The European Association for the Study of Diabetes e.V. (EASD) is a membership-based academic non-profit organization. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany. The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application.

View original content:https://www.prnewswire.co.uk/news-releases/ql-biopharm-announces-abstract-on-novel-ultra-long-acting-glp-1ra-to-be-presented-at-easd-annual-meeting-2024-302236190.html

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

TriNetX’s Founding CEO Announces Plans to Step Down

Published

on

By

After 11 Years, Gadi Lachman to Conclude Operating Role, Remain on TriNetX’s Board

CAMBRIDGE, Mass., Jan. 9, 2025 /PRNewswire/ — TriNetX, the largest global source of real-world data, today announced that Gadi Lachman, the Company’s Founder, President and CEO, will step down from his operating role on March 31, 2025. Gadi founded TriNetX in 2014 and has served as President and CEO in the succeeding 11 years. Gadi will continue to serve on TriNetX’s Board of Directors and will be an Advisor to Carlyle, TriNetX’s majority investor.

“It has been an honor to build TriNetX and be part of such an outstanding team. I want to thank TriNetX’s employees, customers, and shareholders for the support they have shown me. With the talent and passion of our people I am immensely confident in TriNetX’s continued success,” said Lachman. “Together, we have built the largest global platform for clinical research, with data from over 25 countries and tens of millions of queries a month. Our solutions are moving clinical research to a whole different level and saving lives on a massive scale, across all therapeutic areas.”

During the transition period, Jeff Margolis, a current TriNetX Director, will serve as Executive Chairman to ensure continuity in leadership and governance while a CEO search is conducted.

Margolis said, “I have had the distinct privilege of serving on the Board alongside Gadi and partnering with him for 11 years. On behalf of the Board, we thank Gadi for shaping and leading TriNetX to become the world’s top ecosystem of real-world data and real-world evidence serving life sciences and the broader healthcare industry. I look forward to working with him and the rest of the Board over the next months to execute a successful transition of leadership.”

Joe Bress, Partner and Global Co-Head of Healthcare for Carlyle, TriNetX’s lead investor, added, “We have been thrilled to partner with Gadi since our initial investment in TriNetX over four years ago. Thanks to his disciplined leadership, TriNetX is one of the few companies that has sustained profitability even during periods of high growth. Gadi has built the company up to an exciting point, paving the way for a new leader to take the business into its next chapter of growth and success.”

Through this leadership transition, TriNetX remains steadfast in its mission to advance global healthcare through the power of real-world data. The Board, leadership team, and employees are united in their commitment to driving continued innovation and delivering success for customers and partners, all while building on Gadi’s exceptional legacy.

About TriNetX, LLC

TriNetX is a global network of healthcare organizations and life sciences companies dedicated to advancing real-world research and expediting the development of new therapies. Through its self-service, HIPAA-, GDPR-, and LGPD-compliant platform of federated deidentified and anonymous electronic health record datasets and consulting partnerships, TriNetX empowers its global community to improve clinical trial protocol design, streamline trial operations, refine safety signals, and enrich real-world evidence generation. For more information, please visit TriNetX at www.trinetx.com or follow TriNetX on LinkedIn.

Media Contact
TriNetX
Michelle Fleming, Chief Marketing Officer
Email: Michelle.Fleming@TriNetX.com

Logo – https://mma.prnewswire.com/media/542641/TriNetX_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/trinetxs-founding-ceo-announces-plans-to-step-down-302347367.html

Continue Reading

Technology

Stellus Private Credit BDC Announces $0.36 First Quarter 2025 Regular Dividend, Payable Monthly in Increments of $0.12 in January, February, and March 2025

Published

on

By

HOUSTON, Jan. 9, 2025 /PRNewswire/ — Stellus Private Credit BDC (“the Company”) announced that its Board of Trustees has declared a monthly dividend of $0.12 for each of January, February, and March, totaling $0.36 per share in the aggregate for the first quarter of 2025. The regular dividend of $0.36 per share will be paid to shareholders of record in January, February, and March 2025.

Summary of First Quarter 2025 Regular Monthly Dividends

Declared

Record Date

Payment Date

Amount per Share

1/9/2025

1/10/2025

1/31/2025

$0.12

1/9/2025

2/3/2025

2/28/2025

$0.12

1/9/2025

3/3/2025

3/31/2025

$0.12

About Stellus Private Credit BDC

The Company is an externally-managed, closed-end, non-diversified investment management company that has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended. The Company’s investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation by investing primarily in private middle-market companies (typically those with $5.0 million to $50.0 million of EBITDA (earnings before interest, taxes, depreciation and amortization)) through first lien (including unitranche) loans, second lien loans and unsecured debt financing, with corresponding equity co-investments. The Company’s investment activities are managed by its investment adviser, Stellus Private BDC Advisor, LLC.

Forward-Looking Statements

Statements included herein may contain “forward-looking statements” which relate to future performance or financial condition. Statements other than statements of historical facts included in this press release, including statements about COVID-19 and its impacts, may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of assumptions, risks and uncertainties, which change over time. Actual results may differ materially from those anticipated in any forward-looking statements as a result of a number of factors, including those described from time to time in filings by the Company with the Securities and Exchange Commission including the final prospectus that will be filed with the Securities and Exchange Commission. The Company undertakes no duty to update any forward-looking statement made herein. All forward-looking statements speak only as of the date of this press release.

Contacts
Stellus Private Credit BDC
W. Todd Huskinson, Chief Financial Officer
(713) 292-5414
thuskinson@stelluscapital.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/stellus-private-credit-bdc-announces-0-36-first-quarter-2025-regular-dividend-payable-monthly-in-increments-of-0-12-in-january-february-and-march-2025–302347311.html

SOURCE Stellus Private Credit BDC

Continue Reading

Technology

MongoDB, Inc. to Present at the 27th Annual Needham Growth Conference

Published

on

By

NEW YORK, Jan. 9, 2025 /PRNewswire/ — MongoDB, Inc. (NASDAQ: MDB) today announced that Chief Operating Officer and Chief Financial Officer, Michael Gordon, and Senior Vice President of Finance, Serge Tanjga, will present virtually at the 27th Annual Needham Growth Conference.

The MongoDB presentation is scheduled for Thursday, January 16, 2025, at 3:45 p.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the MongoDB investor relations website at https://investors.mongodb.com/news-events/events. A replay of the webcast will also be available for a limited time.

About MongoDB
Headquartered in New York, MongoDB’s mission is to empower innovators to create, transform, and disrupt industries by unleashing the power of software and data. Built by developers, for developers, MongoDB’s developer data platform is a database with an integrated set of related services that allow development teams to address the growing requirements for today’s wide variety of modern applications, all in a unified and consistent user experience. MongoDB has tens of thousands of customers in over 100 countries. The MongoDB database platform has been downloaded hundreds of millions of times since 2007, and there have been millions of builders trained through MongoDB University courses. To learn more, visit mongodb.com.

Investor Relations
Brian Denyeau
ICR for MongoDB
646-277-1251
ir@mongodb.com

Media Relations
MongoDB PR
press@mongodb.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/mongodb-inc-to-present-at-the-27th-annual-needham-growth-conference-302347475.html

SOURCE MongoDB, Inc.

Continue Reading

Trending